


Mechanisms of Tumour Progression Group

Publications: 22

Impact Factor: 114.774

Q1: 14



Research Activity

Doctoral theses

Bustos Tauler J. Relevancia de la proteína lisil oxodasa-like 3 en el desarrollo embrionario y en la iniciación y progresión del melanoma [dissertation]. Madrid: UAM: 2019[25/11/2019].

Directors: Cano García A,
González Santamaria P

Costales Carrera A. Patient-derived normal and tumor colorectal organoids: Studies on gene expression, vitamin D and drug activity [dissertation]. Madrid: UAM: 2019[12/04/2019].

Directors: Muñoz Terol A,
Barbáchano Becerril A.

Publications

• Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradás C, Caffarel MM, Caro-Villalobos M, Uriquén L, Díez-Alarcía R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernardo-Morales C, Arribas J, Canals M,

Casado V, Canela EI, Guzman M, Pérez-Gómez E, Sanchez C. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. *P Natl Acad Sci Usa*. 2019; 116(9): 3863-72. Article. IF: 9.412; Q1

• Calvo-Sánchez MI, Fernández-Martos S, Carrasco E, Moreno-Bueno G, Bernabeu C, Quintanilla M, Espada J. A role for the Tgf-/Bmp co-receptor Endoglin in the molecular oscillator that regulates the hair follicle cycle. *J Mol Cell Biol*. 2019; 11(1):39-52. Article. IF: 4; Q2

• Costales-Carrera A, Fernández-Barral A, Bustamante-Madrid P, Guerra L, Cantero R, Barbachano A, Muñoz A. Plocabulin displays strong cytotoxic activity in a personalized colon cancer patient-derived 3D organoid assay. *Mar Drugs*. 2019; 17(11): 648. Article. IF: 4.073; Q2

• Ferrer-Mayorga G, Larriba MJ, Crespo P, Muñoz A. Mechanisms of action of vitamin D in colon cancer. *J Steroid Biochem*. 2019; 185: 1-6. Review. IF: 3.813; Q2

• Ferrer-Mayorga G, Niell N, Cantero R, González-Sancho JM, del Peso L, Muñoz A, Larriba MJ. Vitamin D and Wnt3A have additive and partially overlapping modulatory effects on gene expres-

sion and phenotype in human colon fibroblasts. *Sci Rep-Uk*. 2019; 9: 8085. Article. IF: 3.998; Q1

• Galindo-Pumarino C, Herrera A, Muñoz A, Carrato A, Herrera M, Peña C. Fibroblast-derived 3D matrix system applicable to endothelial tube formation assay. *J Vis Exp*. 2019; (154): e60304. Article. IF: 1.163; Q3

• Gallardo-Vara E, Ruiz-Llorente L, Casado-Vela J, Ruiz-Rodríguez MJ, López-Andrés N, Pattnaik AK, Quintanilla M, Bernabeu C. Endoglin protein interactome profiling identifies TRIM21 and galectin-3 as new binding partners. *Cells*. 2019; 8(9): 1082. Article. IF: 4.366; Q2

• García-Estévez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. *Breast Cancer Res*. 2019; 21: 35. Review. IF: 4.988; Q2

• Garranzo-Asensio M, Guzmán-Aránguez A, Poves C, Fernández-Acenero MJ, Montero-Calle A, Cerón MA, Fernández-Díez S, Rodríguez N, de Cedrón MG, de Molina AR, Domínguez G, Borderas R. The specific seroreactivity to Delta Np73 isoforms shows higher diagnostic ability in colorectal cancer patients than the canonical p73 protein. *Sci Rep-Uk*. 2019; 9: 13547. Article. IF: 3.998; Q1

• Herrero C, de la Fuente A, Casas-Arozamena C, Sebastián V, Prieto M, Arruebo M, Abalo A, Colas E, Moreno-Bueno G, Gil-Moreno A, Vilar A, Cueva J, Abal M, Muñelo-Romay L. Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer. *Cancers [Basel]*. 2019; 11(12): 2000. Article. IF: 6.126; Q1

• Jiménez-Segovia A, Mota A, Rojo-Sebastián A, Barrocal B, Rynne-Vidal A, García-Bermejo ML, Gómez-Bris R, Hawinkels LJAC, Sandoval P, García-Escudero R, López-Cabrera M, Moreno-Bueno G, Fresno M, Stamatakis K. Prostaglandin F-2 alpha-induced prostate transmembrane protein, androgen induced 1 mediates ovarian cancer progression increasing epithelial plasticity. *Neoplasia*. 2019; 21(11): 1073-84. Article. IF: 5.696; Q1

• Luengo-Gil G, García-Andreo AB, Ortega-Sabater C, Bohdan N, Espin S, Peñas-Martínez J, Martínez-Planes E, García-Hernández A, Vicente V, Quintanilla M, Martínez-Martínez I. Antithrombin is incorporated into exosomes produced by antithrombin non-expressing cells. *Biochimie*. 2019; 165: 245-9. Article. IF: 3.413; Q2

• Majem B, Parrilla A, Jiménez C, Suárez-Cabrera L, Barber M, Marín A, Castellvi J, Tamayo G, Moreno-



- Bueno G, Ponce J, Matías-Guiu X, Alameda F, Romero I, Sánchez JL, Pérez-Benavente A, Morán S, Esteller M, Reventos J, Rigau M, Gil-Moreno A, Segura MF, Santamaría A. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. *Oncogene*. 2019; 38(32): 6035-50. Article. IF: 7,971; D1
- Molina-Crespo A, Cadete A, Sarrio D, Gámez-Chiachio M, Martínez L, Chao K, Olivera A, Gonella A, Díaz E, Palacios J, Dhal PK, Besev M, Rodríguez-Serrano M, Bermejo MLG, Trivino JC, Cano A, García-Fuentes M, Herzberg O, Torres D, Alonso MJ, Moreno-Bueno G. Intracellular delivery of an antibody targeting gasdermin-B reduces HER2 breast cancer aggressiveness. *Clin Cancer Res*. 2019; 25(15): 4846-58. Article. IF: 10.107; D1
 - Moncho-Amor V, Pintado-Berninches L, de Cáceres II, Martín-Villar E, Quintanilla M, Chakravarty P, Cortés-Sempere M, Fernández-Varas B, Rodríguez-Antolín C, de Castro J, Sastre L, Perona R. Role of Dusp6 phosphatase as a tumor suppressor in non-small cell lung cancer. *Int J Mol Sci*. 2019; 20(8): 2036. Article. IF: 4.556; Q1
 - Prieto-Nieto MI, Pastor D, Rodríguez-Cobos J, Pérez JP, Méndez C, Palacios E, Arranz-Álvarez M, Santos-López J, Cano-Vega M, Vinal D, Rodríguez N, Domínguez G. Delta Np73 status in peritoneal and ovarian dissemination of appendicular adenocarcinoids (goblet cells). *Clin Transl Oncol*. 2019; 21(10): 1432-9. Article. IF: 2.737; Q3
 - Quintanilla M, Montero-Montero L, Renart J, Martín-Villar E. Podoplanin in inflammation and cancer. *Int J Mol Sci*. 2019; 20(3): 707. Review. IF: 4.556; Q1
 - Santamaría PG, Mazón MJ, Eraso P, Portillo F. UPR: An upstream signal to EMT induction in cancer. *J Clin Med*. 2019; 8(5): 624. Review. IF: 3.303; Q1
 - Santamaría PG, Moreno-Bueno G, Cano A. Contribution of epithelial plasticity to therapy resistance. *J Clin Med*. 2019; 8(5): 676. Review. IF: 3.303; Q1
 - Santos CP, Lapi E, de Villarreal JM, Álvaro-Espinoza L, Fernández-Barral A, Barbachano A, Domínguez O, Laughney AM, Megías D, Muñoz A, Real FX. Urothelial organoids originating from Cd49f[high] mouse stem cells display Notch-dependent differentiation capacity. *Nat Commun*. 2019; 10: 4407.

Article. IF: 12.121; D1

- Tashkandi M, Ali F, Alsaqer S, Alhousami T, Cano A, Martín A, Salvador F, Portillo F, Gerstenfeld LC, Goldring MB, Bois MV. Lysyl oxidase-like 2 protects against progressive and aging related knee joint osteoarthritis in mice. *Int J Mol Sci*. 2019; 20(19): 4798. Article. IF: 4.556; Q1
- Vázquez-Ríos AJ, Molina-Crespo A, Bouzo BL, López-López R, Moreno-Bueno G, de la Fuente M. Exosome-mimetic nanoplasts for targeted cancer drug delivery. *J Nanobiotechnol*. 2019; 17: 85. Article. IF: 6.518; D1

Research projects

Cano García A. Contribution of LOXL2 and LOXL3 to tumour progression and metastasis (SAF2016-76054-R). MINECO. 2017-2020.

Management centre: UAM

Domínguez Muñoz G. Identificación de los mecanismos implicados en la diseminación peritoneal del cáncer colorrectal. Papel de Deltanp73: implicaciones diagnósticas, pronósticas y terapéuticas (PI18/00473). ISCIII. 2019-2021.

Management centre: FIBHULP

Larriba Muñoz MJ. Efectos de la vitamina D sobre el microentorno tumoral en cáncer de colon (201820I058). CSIC. 2018-2019.

Management centre: CSIC

Moreno Bueno G (IP subgrupo FMDA); Matias-Guiu X (coordinador IDIBELL). Targeting the most aggressive type of endometrial carcinoma. (GCTRA18014MATI). AECC. 2018-2023.

Management centre: FMDA-UAM

Moreno Bueno G. Gasdermina B: mediador de respuesta inflamatoria y terapéutica en cáncer de mama y digestivo. (PI16/00134). ISCIII. 2017-2019.

Management centre: UAM

Moreno Bueno G. Targeting Gasdermin-B overexpression as a new therapeutic approach

in Her2+ cancers. [AECCINVEST-2019GMB]. AECC. 2019-2022.

Management centre: UAM

Muñoz Terol A. Cáncer de colon: efecto de la vitamina D sobre organoides normales y tumorales derivados de pacientes y sobre el microambiente tumoral [VitDColon] (SAF2016-76377-R). Ministerio de Economía y Competitividad, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2017-2020.

Management centre: CSIC

Quintanilla Ávila M, Martín Villar E. Función de podoplanina en la progresión maligna del cáncer epitelial. Relevancia de la interacción podoplanina-CD44 (SAF2017-84183-R). Ministerio de Ciencia, Innovación y Universidades. 2018-2019.

Management centre: IIB "Alberto Sols"

Cibers and Retics

Cano García A, Moreno Bueno G. Networked Biomedical Research Center for Cancer (CIBER-Ronc). ISCIII. (31/12/2022).

Management centre: FIBHULP

Muñoz Terol A. Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2022).

Management centre: FIBHULP

Muñoz Terol A. Red Temática de Receptores Nucleares en Cáncer, Metabolismo e Inflamación. (NuRcMeIn) (SAF2017-90604-REDT). Ministerio de Ciencia, Innovación y Universidades (31/12/2020).

Management centre: FIBHULP

Patents and trademarks

García García JF, Martín Moreno AM, Roncador G, Martínez Torrecuadra JL, Moreno

Bueno G, inventors; Fundación MD Anderson International España, Fundación Centro Nacional de Investigaciones Oncológicas (CNIO), assignees; Method for the diagnosis and/or prognosis of lymphomas. P201231304; 2012 August 14.

Hergueta Redondo M, Sanz PG, Rojo A, García JF, Moreno-Bueno G, inventors; UAM, CSIC, Fundación MD Anderson International España, assignees; Gasdermin B2 as a new biomarker of malignance and resistance of Trastuzumab inhibitor in Her2+ tumors. P201231560; 2012 October 10.

Matías-Guiu Guía FJ, Dolcet Roca FJ, Reventós Puigjaner J, Colás Ortega E, Prat Díaz de Losada J, Palacios Calvo J, Abal Posada M, López López R, Moreno Bueno G, Gil Moreno A, inventors; Institut de Recerca Biomèdica de Lleida Fundació Doctor Pifarré, Universitat de Lleida, Fundació Hospital Universitari Vall d'Hebron-Institut de Recerca, Fundació Institut de Recerca de L'Hospital de la Santa Creu i Sant Pau, Servicio Andaluz de Salud, Servicio Galego de Saúde, Fundación MD Anderson International España, assignees. Method to predict risk of recurrence in endometrial carcinoma. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. EP14155510.2, PCT/EP2015/053387; 2014 February 18.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.